Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5169582 | 0.78 | CA1 (0.55) | CA1EPHX1CA12CA2CA7 | |
| SCHEMBL25008100 | 0.78 | EPHX1 (0.39) | CA1ALDH1A1EPHX1CA2CA7 | |
| SCHEMBL10723265 | 0.74 | EPHX1 (0.56) | CA1ALDH1A1EPHX1CA2CA7 | |
| SCHEMBL6673451 | 0.74 | ALDH1A1 (0.32) | CA1ALDH1A1EPHX1 | |
| SCHEMBL6124862 | 0.74 | EPHX1 (0.56) | CA1ALDH1A1EPHX1CA2CA7 | |
| SCHEMBL13672675 | 0.74 | — | — | |
| SCHEMBL13369989 | 0.74 | CYP2C19 (0.48) | CA1EPHX1CA12CA2CA7 | |
| SCHEMBL10133161 | 0.74 | CA1 (0.58) | CA1ALDH1A1EPHX1CA12CA2 | |
| SCHEMBL10115090 | 0.72 | EPHX1 (0.64) | CA1ALDH1A1EPHX1CA12CA2 | |
| SCHEMBL3784128 | 0.72 | CA12 (0.36) | ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | claimed |
| US-20140088121-A1 | HSP90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-03-27 | — | — | US | claimed |
| EP-2694505-A1 | HSP90 INHIBITORS | Sloan-kettering Institute For Cancer Research (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138894-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-10-11 | — | — | WO | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2023078271-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海旭成医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| EP-0811005-B1 | HERBICIDAL BENZOYL DERIVATIVES | BASF AG (DE) | 1999-09-29 | — | — | EP | disclosed |
| US-5846907-A | Herbicidally active pyrazol-4-ylbenzoyl compounds | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-08 | — | — | US | disclosed |
| US-5846906-A | Herbicidally active phenyldiketone compounds | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-08 | — | — | US | disclosed |
| EP-0815083-A1 | N-AMINOPYRIDONE DERIVATIVES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996037471-A1 | N-AMINOPYRIDONE DERIVATIVES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996026192-A1 | ISOXAZOLYL-BENZOYL DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996026200-A1 | HERBICIDAL BENZOYL DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | CA1 4865/4885ALDH1A1 3813/4885EPHX1 3801/4885 |
| US-20140088121-A1 | HSP90 Inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CA1 1982/4885ALDH1A1 4100/4885EPHX1 2961/4885 |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | CA1 4402/4885ALDH1A1 1352/4885EPHX1 2309/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | CA1 1994/4885ALDH1A1 4061/4885EPHX1 2915/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CA1 3627/4885ALDH1A1 3972/4885EPHX1 4100/4885 |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | CA1 2122/4885ALDH1A1 888/4885EPHX1 1835/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | CA1 4847/4885ALDH1A1 3857/4885EPHX1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.